“ASSESSMENT OF CARDIOVASCULAR AND RENAL OUTCOMES FOLLOWING DAPAGLIFLOZIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE”, A-JMRHS, vol. 4, no. 2, pp. 1398–1403, Jun. 2026, doi: 10.65605/a-jmrhs.2026.v04.i02.pp1398-1403.